Cancer driver genes in luminal and triple negative breast cancer from young women.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13527-e13527
Author(s):  
Simone Maistro ◽  
Ana Carolina Ribeiro Chaves De Gouvea ◽  
Gláucia Fernanda de Lima Pereira ◽  
Maria Lucia Hirata Katayama ◽  
Lívia Munhoz Rodrigues ◽  
...  
Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 632
Author(s):  
Masood Zaka ◽  
Chris W. Sutton ◽  
Yonghong Peng ◽  
Savas Konur

Background: miRNAs (microRNAs) play a key role in triple-negative breast cancer (TNBC) progression, and its heterogeneity at the expression, pathological and clinical levels. Stratification of breast cancer subtypes on the basis of genomics and transcriptomics profiling, along with the known biomarkers’ receptor status, has revealed the existence of subgroups known to have diverse clinical outcomes. Recently, several studies have analysed expression profiles of matched mRNA and miRNA to investigate the underlying heterogeneity of TNBC and the potential role of miRNA as a biomarker within cancers. However, the miRNA-mRNA regulatory network within TNBC has yet to be understood. Results and Findings: We performed model-based integrated analysis of miRNA and mRNA expression profiles on breast cancer, primarily focusing on triple-negative, to identify subtype-specific signatures involved in oncogenic pathways and their potential role in patient survival outcome. Using univariate and multivariate Cox analysis, we identified 25 unique miRNAs associated with the prognosis of overall survival (OS) and distant metastases-free survival (DMFS) with “risky” and “protective” outcomes. The association of these prognostic miRNAs with subtype-specific mRNA genes was established to investigate their potential regulatory role in the canonical pathways using anti-correlation analysis. The analysis showed that miRNAs contribute to the positive regulation of known breast cancer driver genes as well as the activation of respective oncogenic pathway during disease formation. Further analysis on the “risk associated” miRNAs group revealed significant regulation of critical pathways such as cell growth, voltage-gated ion channel function, ion transport and cell-to-cell signalling. Conclusion: The study findings provide new insights into the potential role of miRNAs in TNBC disease progression through the activation of key oncogenic pathways. The results showed previously unreported subtype-specific prognostic miRNAs associated with clinical outcome that may be used for further clinical evaluation.


Author(s):  
S Panjarian ◽  
J Madzo ◽  
C Slater ◽  
J Jelinek ◽  
X Chen ◽  
...  

2014 ◽  
Vol 31 (12) ◽  
Author(s):  
Ying Liu ◽  
Tao Xin ◽  
Da-yong Huang ◽  
Wei-xi Shen ◽  
Li Li ◽  
...  

Genes ◽  
2020 ◽  
Vol 11 (11) ◽  
pp. 1367
Author(s):  
Ernesto Rojas-Jiménez ◽  
Javier César Mejía-Gómez ◽  
Clara Díaz-Velásquez ◽  
Rosalía Quezada-Urban ◽  
Héctor Martínez Gregorio ◽  
...  

Triple-negative breast cancer (TNBC) presents a marked diversity at the molecular level, which promotes a clinical heterogeneity that further complicates treatment. We performed a detailed whole exome sequencing profile of 29 Mexican patients with long follow-up TNBC to identify genomic alterations associated with overall survival (OS), disease-free survival (DFS), and pathologic complete response (PCR), with the aim to define their role as molecular predictive factors of treatment response and prognosis. We detected 31 driver genes with pathogenic mutations in TP53 (53%), BRCA1/2 (27%), CDKN1B (9%), PIK3CA (9%), and PTEN (9%), and 16 operative mutational signatures. Moreover, tumors with mutations in BRCA1/2 showed a trend of sensitivity to platinum salts. We found an association between deficiency in DNA repair and surveillance genes and DFS. Across all analyzed tumors we consistently found a heterogeneous molecular complexity in terms of allelic composition and operative mutational processes, which hampered the definition of molecular traits with clinical utility. This work contributes to the elucidation of the global molecular alterations of TNBC by providing accurate genomic data that may help forthcoming studies to improve treatment and survival. This is the first study that integrates genomic alterations with a long follow-up of clinical variables in a Latin American population that is an underrepresented ethnicity in most of the genomic studies.


BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
SR Young ◽  
Robert T Pilarski ◽  
Talia Donenberg ◽  
Charles Shapiro ◽  
Lyn S Hammond ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Xiao-wei Du ◽  
Gao Li ◽  
Juan Liu ◽  
Chun-yan Zhang ◽  
Qiong Liu ◽  
...  

Abstract Background Breast cancer is the most common malignancy in women. Cancer driver gene-mediated alterations in the tumor microenvironment are critical factors affecting the biological behavior of breast cancer. The purpose of this study was to identify the expression characteristics and prognostic value of cancer driver genes in breast cancer. Methods The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets are used as the training and test sets. Classified according to cancer and paracancerous tissues, we identified differentially expressed cancer driver genes. We further screened prognosis-associated genes, and candidate genes were submitted for the construction of a risk signature. Functional enrichment analysis and transcriptional regulatory networks were performed to search for possible mechanisms by which cancer driver genes affect breast cancer prognosis. Results We identified more than 200 differentially expressed driver genes and 27 prognosis-related genes. High-risk group patients had a lower survival rate compared to the low-risk group (P<0.05), and risk signature showed high specificity and sensitivity in predicting the patient prognosis (AUC 0.790). Multivariate regression analysis suggested that risk scores can independently predict patient prognosis. Further, we found differences in PD-1 expression, immune score, and stromal score among different risk groups. Conclusion Our study confirms the critical prognosis role of cancer driver genes in breast cancer. The cancer driver gene risk signature may provide a novel biomarker for clinical treatment strategy and survival prediction of breast cancer.


2017 ◽  
pp. 141-158
Author(s):  
Narjust Duma ◽  
Ciara C. O’Sullivan ◽  
Kathryn J. Ruddy ◽  
Alexis D. Leal

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e23192-e23192 ◽  
Author(s):  
Xiaosong Zhang ◽  
Meng Li ◽  
Olga Momcilovic ◽  
Andrew Beardsley ◽  
Roman Camarda ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document